The challenges of introducing routine G6PD testing into radical cure: A workshop report

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Ley, Benedikt ^a   Luter, Nick ^b   Espino, Fe Esperanza ^c   Devine, Angela ^d,f   Kalnoky, Michael ^b   Lubell, Yoel ^c,f   Thriemer, Kamala ^a   Baird, J Kevin ^e,f   Poirot, Eugenie ^g   Conan, Nolwenn ^h   Kheong, Chong Chee ⁱ   Dysoley, Lek ^j,k   Khan, Wasif Ali ^l   Dion Berboso, April G ^m   Bancone, Germana ⁿ   Hwang, Jimee ^g,o   Kumar, Ritu ^b   Price, Ric N ^a,f   Von Seidlein, Lorenz ^d,f   Domingo, Gonzalo J ^b  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b PATH   (United States)

^c RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^d MAHIDOL UNIVERSITY   (Thailand)

^e OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Malaria Consortium   (Thailand)

ⁱ MINISTRY OF HEALTH   (Malaysia)

^j National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^k National Institute of Public Health   (Cambodia)

^l INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^m UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

ⁿ SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^o CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

G6PD; Malaria; Plasmodium vivax; Point of care test; Primaquine

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PRIMAQUINE; ANTIMALARIAL AGENT;

ANEMIA; ARTICLE; BANGLADESH; BIOSENSOR; CAMBODIA; COST EFFECTIVENESS ANALYSIS; DISEASE ELIMINATION; DISEASE TRANSMISSION; ECONOMIC EVALUATION; ENZYME ACTIVITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE RAPID DIAGNOSTIC TEST; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEMOLYSIS; HUMAN; INCIDENCE; MALARIA FALCIPARUM; MALAYSIA; NEWBORN SCREENING; NONHUMAN; OUTCOME ASSESSMENT; PHILIPPINES; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POINT OF CARE TESTING; PRACTICE GUIDELINE; PREVALENCE; QUALITATIVE ANALYSIS; RAPID TEST; RECURRENT DISEASE; RELAPSE; RISK BENEFIT ANALYSIS; SPECTROPHOTOMETRY; ULTRAVIOLET RADIATION; FEMALE; GENETICS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; MALARIA, VIVAX; MALE; POINT OF CARE SYSTEM;

ANTIMALARIALS; FEMALE; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX; POINT-OF-CARE SYSTEMS; PRIMAQUINE;

EID: 84942421382     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0896-8     Document Type: Article

References (53)

1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6 Suppl):79-87.
2. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555-66. doi: 10.1016/S1473-3099(09)70177-X.
3. Carlton JM, Sina BJ, Adams JH. Why is Plasmodium vivax a neglected tropical disease? PLoS Neglect Trop Dis. 2011;5:e1160. doi: 10.1371/journal.pntd.0001160.
4. Price RN. Improving the radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg. 2014;91:3-4. doi: 10.4269/ajtmh.14-0118.
5. Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010;54:792-8. doi: 10.1128/AAC.00354-09.
6. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418. doi: 10.1186/1475-2875-13-418.
7. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. doi: 10.1186/1475-2875-12-112.
8. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015.
9. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391. doi: 10.1186/1475-2875-12-391.
10. MPAC. Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. Geneva: World Health Organization; 2015.
11. Manganelli G, Masullo U, Passarelli S, Filosa S. Glucose-6-phosphate dehydrogenase deficiency: disadvantages and possible benefits. Cardiovasc Hematol Disord Drug Targets. 2013;13:73-82.
12. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133-201. doi: 10.1016/B978-0-12-407826-0.00004-7.
13. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008;111:16-24. doi: 10.1182/blood-2007-04-077412.
14. Gomez-Manzo S, Terron-Hernandez J, la Mora-De De, la Mora I, Gonzalez-Valdez A, Marcial-Quino J, Garcia-Torres I, et al. The stability of G6PD is affected by mutations with different clinical phenotypes. Int J Mol Sci. 2014;15:21179-201. doi: 10.3390/ijms151121179.
15. Kotaka M, Gover S, Vandeputte-Rutten L, Au SW, Lam VM, Adams MJ. Structural studies of glucose-6-phosphate and NADP+ binding to human glucose-6-phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr. 2005;61(Pt 5):495-504. doi: 10.1107/S0907444905002350.
16. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67:601-11.
17. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64-74. doi: 10.1016/S0140-6736(08)60073-2.
18. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the "old" and update of the new mutations. Blood Cells Mol Dis. 2012;48:154-65. doi: 10.1016/j.bcmd.2012.01.001.
19. Leslie T, Briceno M, Mayan I, Mohammed N, Klinkenberg E, Sibley CH, et al. The impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med. 2010;7:e1000283. doi: 10.1371/journal.pmed.1000283.
20. Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science. 2009;326:1546-9. doi: 10.1126/science.1178849.
21. Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164:469-80. doi: 10.1111/bjh.12665.
22. Johnson MK, Clark TD, Njama-Meya D, Rosenthal PJ, Parikh S. Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. PLoS One. 2009;4:e7246. doi: 10.1371/journal.pone.0007246.
23. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339. doi: 10.1371/journal.pmed.1001339.
24. Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007;21:267-83. doi: 10.1016/j.blre.2007.05.002.
25. Meissner PE, Coulibaly B, Mandi G, Mansmann U, Witte S, Schiek W, et al. Diagnosis of red cell G6PD deficiency in rural Burkina Faso: comparison of a rapid fluorescent enzyme test on filter paper with polymerase chain reaction based genotyping. Br J Haematol. 2005;131:395-9. doi: 10.1111/j.1365-2141.2005.05778.x.
26. Chiu DT, Zuo L, Chao L, Chen E, Louie E, Lubin B, et al. Molecular characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency in patients of Chinese descent and identification of new base substitutions in the human G6PD gene. Blood. 1993;81:2150-4.
27. LaRue N, Kahn M, Murray M, Leader BT, Bansil P, McGray S, et al. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2014;91:854-61. doi: 10.4269/ajtmh.14-0194.
28. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW. Noninferiority of glucose-6-phosphate dehydrogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test demonstrated by copper inhibition in normal human red blood cells. Transl Res. 2014;165:677-80. doi: 10.1016/j.trsl.2014.09.009.
29. Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia. PLoS One. 2014;9:e116143. doi: 10.1371/journal.pone.0116143.
30. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg. 2015;92:818-24. doi: 10.4269/ajtmh.14-0696.
31. Nantakomol D, Paul R, Palasuwan A, Day NP, White NJ, Imwong M. Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. Malar J. 2013;12:289. doi: 10.1186/1475-2875-12-289.
32. Ainoon O, Alawiyah A, Yu YH, Cheong SK, Hamidah NH, Boo NY, et al. Semiquantitative screening test for G6PD deficiency detects severe deficiency but misses a substantial proportion of partially-deficient females. Southeast Asian J Trop Med Public Health. 2003;34:405-14.
33. Peters AL, Van Noorden CJ. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem. 2009;57:1003-11. doi: 10.1369/jhc.2009.953828.
34. Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, et al. A novel cytofluorometric assay for the detection and quantification of glucose-6-phosphate dehydrogenase deficiency. Sci Rep. 2012;2:299. doi: 10.1038/srep00299.
35. PATH. A Guide to Fluorescnt Spot Testing for G6PD Deficiency. Programme for Appropriate Technology in Health, 2014.
36. De Niz M, Eziefula AC, Othieno L, Mbabazi E, Nabukeera D, Ssemmondo E, et al. Tools for mass screening of G6PD deficiency: validation of the WST8/1-methoxy-PMS enzymatic assay in Uganda. Malar J. 2013;12:210. doi: 10.1186/1475-2875-12-210.
37. Tinley KE, Loughlin AM, Jepson A, Barnett ED. Evaluation of a rapid qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg. 2010;82:210-4. doi: 10.4269/ajtmh.2010.09-0416.
38. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLoS One. 2011;6:e28357. doi: 10.1371/journal.pone.0028357.
39. Osorio L, Carter N, Arthur P, Bancone G, Gopalan S, Gupta SK, et al. Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects. Am J Trop Med Hyg. 2015;92:22-7. doi: 10.4269/ajtmh.14-0298.
40. Baird JK, Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol. 2011;27:11-6. doi: 10.1016/j.pt.2010.08.005.
41. Beutler E, Duparc S, G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779-89.
42. Brewer GJ, Powell RD, Swanson SH, Alving AS. Hemolytic effect of primaquine. Xvii. Hexokinase activity of glucose-6-phosphate dehydrogenase-deficient and normal erythrocytes. J Lab Clin Med. 1964;64:601-12.
43. Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13:203. doi: 10.1186/s12916-015-0441-1.
44. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612-20. doi: 10.1093/cid/ciq249.
45. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis. 2012;206:1771-80. doi: 10.1093/infdis/jis580.
46. Peixoto HM, Brito MA, Romero GA, Monteiro WM, de Lacerda MV, de Oliveira MR. G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study. Malar J. 2015;14:126. doi: 10.1186/s12936-015-0647-x.
47. WHO. World Malaria Report 2013. Geneva: World Health Organization; 2014.
48. WHO. Eliminating malaria: case study 8. Progress towards elimination in Malaysia. Geneva: World Health Organization; 2015.
49. Leong YH, Gan CY, Tan MA, Majid MI. Present status and future concerns of expanded newborn screening in malaysia: sustainability, challenges and perspectives. Malays J Med Sci. 2014;21:63-7.
50. The Global Fund to Fight AIDS TaM. Philippines. 2015. http://portfolio.theglobalfund.org/en/Country/Index/PHL. Accessed 07.09.2015.
51. APMEN. APMEN-PATH CONSULTATION: Strategies to implement G6PD screening to achieve successful radical cure of P. vivax in endemic countries. 2015. http://apmen.org/path-vivax-meeting-2015/. Accessed 07.09.2015.
52. CNM. National treatment guidelines for malaria in Cambodia. Minister of Health, editor. Phnom Penh, 2015. http://whothailand.healthrepository.org/bitstream/123456789/1442/1/NTG%20in%20English-Final.pdf.
53. von Fricken ME, Weppelmann TA, Eaton WT, Masse R, Madsen VE, De Rochars B, et al. Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti. Am J Trop Med Hyg. 2014;91:77-80. doi: 10.4269/ajtmh.14-0100.